Published in BMC Cancer on October 16, 2015
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. Oncotarget (2016) 0.77
Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines. J Cancer (2017) 0.75
Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol (2010) 10.70
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res (2007) 7.42
Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract (2010) 7.41
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2010) 4.36
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Use of thiazolidinediones and fracture risk. Arch Intern Med (2008) 2.99
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
The general practice research database: role in pharmacovigilance. Drug Saf (2004) 2.38
The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) (2008) 2.23
Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) (2010) 2.18
Nonradiation risk factors for thyroid cancer in the US Radiologic Technologists Study. Am J Epidemiol (2009) 1.74
Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf (2012) 1.62
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab (2003) 1.47
Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol (2008) 1.42
Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev (2010) 1.39
BMI, diet and female reproductive factors as risks for thyroid cancer: a systematic review. PLoS One (2012) 1.39
Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol (2011) 1.38
Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab (2001) 1.35
Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab (2012) 1.25
Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nat Clin Pract Endocrinol Metab (2005) 1.19
Cigarette smoking, alcohol intake, and thyroid cancer risk: a pooled analysis of five prospective studies in the United States. Cancer Causes Control (2012) 1.19
Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer (2012) 1.17
Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab (2013) 1.05
Diabetes and thyroid cancer risk: literature review. Exp Diabetes Res (2012) 1.02
Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid (2004) 1.02
Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer (2005) 1.00
Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. J Am Acad Dermatol (2008) 0.97
Thyroid cancer risk is not increased in diabetic patients. PLoS One (2012) 0.96
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun (2004) 0.96
Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer (2012) 0.96
Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes. PLoS One (2014) 0.94
The changing face of thyroid cancer in a population-based cohort. Cancer Med (2013) 0.91
Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway. Biochem Pharmacol (2011) 0.85
Does use of metformin protect against cancer in Type 2 diabetes mellitus? J Endocrinol Invest (2012) 0.85
Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. Mol Cell Endocrinol (2014) 0.84
Hyperthyroidism and thyroid cancer risk: a population-based cohort study. Exp Clin Endocrinol Diabetes (2013) 0.84
AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer. Eur J Endocrinol (2013) 0.83
AMP-activated protein kinase upregulates glucose uptake in thyroid PCCL3 cells independent of thyrotropin. Thyroid (2012) 0.83
Rosuvastatin induces apoptosis in cultured human papillary thyroid cancer cells. J Endocrinol (2011) 0.82
A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab (2015) 0.80
Impact of Metformin and compound C on NIS expression and iodine uptake in vitro and in vivo: a role for CRE in AMPK modulation of thyroid function. Thyroid (2013) 0.80
Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood) (2008) 0.78
Glucose transporters in the thyroid. Thyroid (2005) 0.78
Antitumor activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in medullary thyroid carcinoma. Mol Med Rep (2013) 0.77